Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

Isamu Okamoto, Byoung Chul Cho, Sarah B. Goldberg, Jonathan W. Goldman, Adrianus J. de Langen, Zofia Piotrowska, Jonathan W. Riess, Helena A. Yu, M Rosario Garcia Campelo, Jeremy Cetnar, Yu Jung Kim, Silvia Novello, Yoshimasa Shiraishi, Helen Ambrose, Paul E. Smith, Kwan Ho Tang, Jonathan M. Lehman, Xiuning Le

Open source

DOI: 10.1016/j.lungcan.2026.109501
Published: 2026-08
Container: Lung Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2026.109501,
  title = {Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD},
  author = {Isamu Okamoto and Byoung Chul Cho and Sarah B. Goldberg and Jonathan W. Goldman and Adrianus J. de Langen and Zofia Piotrowska and Jonathan W. Riess and Helena A. Yu and M Rosario Garcia Campelo and Jeremy Cetnar and Yu Jung Kim and Silvia Novello and Yoshimasa Shiraishi and Helen Ambrose and Paul E. Smith and Kwan Ho Tang and Jonathan M. Lehman and Xiuning Le},
  year = {2026},
  journal = {Lung Cancer},
  doi = {10.1016/j.lungcan.2026.109501},
  url = {https://doi.org/10.1016/j.lungcan.2026.109501}
}

RIS

TY  - JOUR
TI  - Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD
AU  - Isamu Okamoto
AU  - Byoung Chul Cho
AU  - Sarah B. Goldberg
AU  - Jonathan W. Goldman
AU  - Adrianus J. de Langen
AU  - Zofia Piotrowska
AU  - Jonathan W. Riess
AU  - Helena A. Yu
AU  - M Rosario Garcia Campelo
AU  - Jeremy Cetnar
AU  - Yu Jung Kim
AU  - Silvia Novello
AU  - Yoshimasa Shiraishi
AU  - Helen Ambrose
AU  - Paul E. Smith
AU  - Kwan Ho Tang
AU  - Jonathan M. Lehman
AU  - Xiuning Le
PY  - 2026
JO  - Lung Cancer
DO  - 10.1016/j.lungcan.2026.109501
UR  - https://doi.org/10.1016/j.lungcan.2026.109501
ER  -

APA

Okamoto, I., Cho, B. C., Goldberg, S. B., Goldman, J. W., Langen, A. J. D., Piotrowska, Z., Riess, J. W., Yu, H. A., Campelo, M. R. G., Cetnar, J., Kim, Y. J., Novello, S., Shiraishi, Y., Ambrose, H., Smith, P. E., Tang, K. H., Lehman, J. M., & Le, X. (2026). Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD. Lung Cancer. https://doi.org/10.1016/j.lungcan.2026.109501

Source records

crossref · retrieved 2026-09-26T06:05:42.692Z